TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration tri… Read more
TuHURA Biosciences Inc (HURA) - Total Liabilities
Latest total liabilities as of September 2025: $8.92 Million USD
Based on the latest financial reports, TuHURA Biosciences Inc (HURA) has total liabilities worth $8.92 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TuHURA Biosciences Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how TuHURA Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TuHURA Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of TuHURA Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Türk Traktör ve Ziraat Makineleri A.S
PINK:TTRKF
|
USA | $24.86 Billion |
|
UHT Unitech Co., Ltd.
TWO:6618
|
Taiwan | NT$72.66 Million |
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
USA | $238.96 Million |
|
Nekkar Asa
OL:NKR
|
Norway | Nkr447.24 Million |
|
Kestrel Group, Ltd.
NYSE:KG
|
USA | $986.67 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down TuHURA Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TuHURA Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TuHURA Biosciences Inc (2014–2025)
The table below shows the annual total liabilities of TuHURA Biosciences Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $5.37 Million | -9.25% |
| 2024-06-30 | $5.92 Million | +104.67% |
| 2023-06-30 | $2.89 Million | -59.54% |
| 2022-06-30 | $7.15 Million | +141.39% |
| 2021-06-30 | $2.96 Million | +10.73% |
| 2020-06-30 | $2.67 Million | +29.24% |
| 2019-06-30 | $2.07 Million | +26.23% |
| 2018-06-30 | $1.64 Million | +23.05% |
| 2017-06-30 | $1.33 Million | -10.99% |
| 2016-06-30 | $1.50 Million | -55.93% |
| 2015-06-30 | $3.40 Million | -33.87% |
| 2014-06-30 | $5.14 Million | -- |